Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Indication: Darolutamide in Androgen Receptor Positive Salivary Gland Carcinoma
The DISCOVARY trial investigated darolutamide as monotherapy and in combination with goserelin in patients with AR-positive salivary gland carcinoma. The combination cohort demonst
New Protocol: Atezolizumab with FOLFOX and Bevacizumab for Metastatic MSI-H Colorectal Cancer
In this randomized phase 3 study, mFOLFOX6/bevacizumab/atezolizumab significantly improved progression-free survival compared with atezolizumab alone in patients with deficient DNA
New Protocol: Belzutifan with Lenvatinib for Advanced Clear Cell RCC
The LITESPARK-011 study demonstrated that belzutifan plus lenvatinib significantly improved progression-free survival and objective response rate compared to cabozantinib in patien
New Reference: Switching to Camizestrant at ESR1 Mutation Emergence in Breast Cancer
In patients with hormone receptor-positive advanced breast cancer with emergent ESR1 mutation while on first-line aromatase inhibitor plus CDK4/6 inhibitor, switching to camizestra
New Indication: Dabrafenib + Trametinib for bRAF V600E Mutated Differentiated Thyroid Cancer
This phase 3 randomized study evaluated dabrafenib plus trametinib versus placebo in patients with radioactive iodine-refractory BRAFV600E-positive differentiated thyroid cancer. T
New Reference: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
In this phase 3 trial, perioperative enfortumab vedotin-pembrolizumab demonstrated significantly better event-free survival and overall survival compared to neoadjuvant cisplatin-g
New Reference: Long-Term Results of Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
This long-term analysis of randomized phase 3 trial of enzalutamide compared to a non-steroidal anti-androgen (NSAA) when added to testosterone suppression for metastatic hormone-s
New Reference: Long-Term Results for Nivolumab in Advanced Esophageal SCC
In the CheckMate 648 study with 5-year follow-up, nivolumab plus chemotherapy and nivolumab plus ipilimumab continued to demonstrate clinically meaningful survival benefit versus c
New Indication: First-Line Pemigatinib for FGFR2 Rearranged Cholangiocarcinoma
The FIGHT-302 trial evaluated pemigatinib against gemcitabine plus cisplatin as a first-line treatment for advanced cholangiocarcinoma with FGFR2 rearrangements. Pemigatinib signif
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.